Format

Send to

Choose Destination
Hosp Pharm. 2017 Jul;52(7):469-470. doi: 10.1177/0018578717726517. Epub 2017 Sep 11.

Chimeric Antigen Receptor T-Cell Therapy for Lymphomas.

Author information

1
St. Louis College of Pharmacy, MO, USA.
2
Prescribe Right, LLC, Wildwood, MO, USA.

Abstract

It is estimated that 2.1% of the population of the United States will develop non-Hodgkin lymphoma (NHL) in a lifetime. With treatment, 71% of patients with NHL live to 5 years. Because current drugs used for treatment do not cure all patients and cause serious adverse effects, new strategies have been studied to treat lymphoma. One new pharmacologic strategy is to use chimeric antigen receptor T-cell (CAR T-cell) therapy. CAR T-cell therapies are very potent. As a class, the CAR T-cell therapies have induced complete remission in 50% to 80% of patients. Most patients using CAR T-cell therapies develop cytokine release syndrome, with about 1 in 3 having a severe form of the syndrome. This article will briefly review CAR T-cell therapies in development.

KEYWORDS:

formulary management/P&T; investigational drugs; oncology

Conflict of interest statement

Declaration of Conflicting Interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center